

RECEIVED
FEB 21 2002
TECH CENTER 1600/2900


wherein:

n is an integer from 2-8;

X_1 is a cholic acid group or deoxycholic acid group; and X_2 and X_3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of X_2 and X_3 is a saccharide group.

1 22. (Amended) A pharmaceutical composition comprising a mucoadhesive and a
2 therapeutically effective amount of a therapeutic agent formulated in a buffer comprising a
3 compound of Formula I:




5 wherein:

6 *n* is an integer from 2-8;

7 X_1 is a cholic acid group or deoxycholic acid group; and X_2 and X_3 are each
8 independently selected from the group consisting of a cholic acid group, a deoxycholic acid group,
9 and a saccharide group, wherein the saccharide group is selected from the group consisting of
10 pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide
11 groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-
12 pentose disaccharide groups;

13 and wherein at least one of X_2 and X_3 is a saccharide group.

1 35. (Amended) A method of treating bladder cancer comprising administration to a
2 cell of a therapeutically effective amount of a therapeutic gene that is formulated in a buffer, wherein
3 the therapeutically effective amount of a therapeutic gene is in the range of about from 1×10^8
4 particles/ml to 5×10^{11} particles/ml of a recombinant adenovirus in which the therapeutic gene is
5 inserted, comprising a compound of Formula I:




7 wherein:

8 n is an integer from 2-8;

9 X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each
10 independently selected from the group consisting of a cholic acid group, a deoxycholic acid group,
11 and a saccharide group, wherein the saccharide group is selected from the group consisting of
12 pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide
13 groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-
14 pentose disaccharide groups;

15 and wherein at least one of X2 and X3 is a saccharide group.

1 36. (Amended) A method of treating bladder cancer comprising administration to a
2 cell of a therapeutically effective amount of a therapeutic gene that is formulated in a buffer, wherein
3 the therapeutically effective amount of a therapeutic gene is in the range of about from 1×10^9
4 particles/ml to 5×10^{11} particles/ml of a recombinant adenovirus in which the therapeutic gene is
5 inserted, comprising a compound of Formula I:



7 wherein:

8 n is an integer from 2-8;